מחיר ריאלי לרכישת החברה במלואה: harmonybiosciences.com (HRMY)

Harmony Biosciences (HRMY) is actively expanding its portfolio of therapies for rare brain pathologies by acquiring promising biotech projects. The brand maintains absolute authority among medical professionals due to its effectiveness in treating sleep disorders. This price chart on GURU.Markets shows an Enterprise Value of 1800.52, while market capitalization depends on the volume of Wakix prescriptions and FDA approval for new indications.

Enterprise Value (EV) represents the total acquisition cost of a business, combining market capitalization and net debt. By analyzing the company's gross value, an investor sees the actual cost of acquiring the asset. For Harmony Biosciences (HRMY), this metric reflects the financial capacity for aggressive expansion of its orphan drug portfolio. The trend in the company's gross value confirms its readiness to acquire new biotech startups, allowing for an objective assessment of the efficiency of invested capital.